Search
Oxford, UK based Brainomix has developed an AI based platform that is designed to help hospitals diagnose the existence and severity of strokes from scans quickly as every minute counts
CEO Michalis Papadakis describes the technology and how it has the potential to greatly increase the number of people who experience stroke, and more quickly. The platform is FDA-cleared and CE-marked in Europe, and in wide use in Europe today. The company is also working on a lung fibrosis diagnostic.
Jul 20
Brainomix, an Oxford, UK based company that uses AI to help front line physicians analyze CT scans for stroke damage and interstitial lung disease, announced an $18M series C raise today
Co-Founder and CEO Michalis Papadakis describes the unmet need for a quick, accurate assessment of stroke damage by front line...
Mar 20, 2025
.png){kind=logo}